Día mundial del Mieloma Múltiple - Somosdisc@

Cada 5 de septiembre se celebra el día mundial del Mieloma Múltiple, para visibilizar este tipo de cáncer que se desarrolla en la sangre

Giornata nazionale della lotta a leucemia, linfomi e mieloma

Nessun segno che potesse anticipare tutto quello che è successo alla mia mamma.

Inmunoterapia, potenciando al sistema inmunitario en la detección de cáncer

Inmunoterapia, potenciando al sistema inmunitario en la detección de cáncer Tendencias - El Mundo CR

Día mundial del Mieloma Múltiple 2024 - Somosdisc@

Cada 5 de septiembre se celebra el día mundial del Mieloma Múltiple, visibilizando este tipo de cáncer que se desarrolla en la sangre.

An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously - Cancer Gene Therapy

Chimeric antigen receptor T (CAR-T) cells therapy has made remarkable progress in relapsed/refractory multiple myeloma (R/R MM) treatment. Unfortunately, patients still eventually experience disease progression or relapse even after receiving anti-BCMA CAR-T therapy. At present, there are limited data on available treatment options for patients who have progressed on anti-BCMA CAR-T therapy. In this study, we evaluated the safety and efficacy of fully human anti-BCMA CAR-T (HRC0202) in seven R/R MM patients who were previously exposed to anti-BCMA CAR-T therapy. Three patients received 6.0 × 106 CAR+T cells/kg, one patient received 10.0 × 106 CAR+T cells/kg and three patients received 15.0 × 106 CAR+T cells/kg. Cytokine release syndrome (CRS) of grades 1–2 occurred in three patients (42.9%) and grade ≥3 in two patients (28.6%). Immune effector cell-associated neurotoxic syndrome (ICANS) was not observed in any of the patients. The best overall response rate (ORR) was 71.4% (5/7), with a stringent complete response/complete response (sCR/CR) achieved in three patients. The median progression-free survival (PFS) was 269 days, and median overall survival (OS) for all patients was not reached. The median peak concentration (Cmax) of HRC0202 was 30117.70 (range, 6084.35–147415.10) copies/μg DNA. This study indicated that fully human anti-BCMA CAR-T (HRC0202) is a promising treatment for R/R MM patients who relapsed or refractory from prior anti-BCMA CAR-T infusion.

Día mundial del Mieloma Múltiple 2023 - Somosdisc@

Cada 5 de septiembre se celebra el día mundial del Mieloma Múltiple, con el objetivo de visibilizar este tipo de cáncer.

Mieloma: le lunghe liste d'attesa offuscano i progressi delle cure in Italia

L'accesso ai farmaci per il mieloma resta "difficile" in Francia

Mieloma: una terapia innovativa è stata sviluppata in Germania